Form 4: Spyre Therapeutics CFO Sells Shares to Cover Tax Obligations

Scott L. Burrows, CFO of Spyre Therapeutics, sold 18,531 shares of common stock to cover tax liabilities related to the settlement of restricted stock units.

Summary

• On September 3, 2024, Scott L. Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), sold 18,531 shares of the company's common stock.
• The sale was executed to cover the reporting person's tax liability associated with the settlement of 33,739 restricted stock units (RSUs).
• The shares were sold at a weighted average price of $28.173, with individual transactions ranging from $27.72 to $28.18.
• Following the transaction, Burrows still beneficially owns 116,422 shares, which includes 101,214 RSUs that vest in three equal installments on September 1, 2025, 2026, and 2027, contingent upon continued employment with the Issuer.

Sentiment

Score: 5

Explanation: This is a neutral event. The sale is related to tax obligations and doesn't necessarily reflect a change in the executive's outlook on the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a routine Form 4 filing, reflecting a common practice of executives selling shares to cover tax obligations related to equity compensation. It doesn't necessarily indicate a change in the executive's confidence in the company.

Key Dates